Literature DB >> 12485860

Increased in vitro cytotoxicity of TNF-alpha analog LK-805 is based on the interaction with cell surface heparan sulfate proteoglycan.

Viktor Menart1, Irena Fonda, Maja Kenig, Vladka Gaberc Porekar.   

Abstract

Our tumor necrosis factor-alpha (TNF-alpha) analog LK-805 (E107K) exhibited twofold higher specific cytotoxicity on the mouse fibroblast L-929 cell line than its native counterpart. In addition, significantly lowered systemic toxicity was observed in tumor-bearing mouse models treated with this analog. Due to a charge reversal and clustering of three lysines in the exposed tip region of LK-805, we assumed that additional ionic interactions between the positively charged TNF analog and the negatively charged components of the cell surface were created, which might contribute to improved properties of LK-805. To prove this hypothesis, we designed truncated forms of TNF-alpha and analog LK-805 and performed three independent sets of experiments: measurement of cytotoxic activity in the presence of excess heparan sulfate, determination of cytotoxic activity on heparinase-treated L-929 cells, and binding of various TNF-alpha proteins onto the heparin-sepharose affinity column. Cytotoxicity studies of both kinds confirmed the pivotal role of the E107K mutation for interaction with heparan sulfate proteoglycans on the cell surface of L-929 cells. However, heparin-binding studies revealed that intact, full-length N-termini of TNF-alpha or its analogs were necessary for high retention on the heparin affinity column, whereas the three-lysine containing tip of LK-805 by itself was not enough for binding. Obviously, immobilized heparin does not represent an adequate model for membrane-bound heparan sulfate proteoglycans of L-929 cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12485860     DOI: 10.1111/j.1749-6632.2002.tb04632.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  3 in total

Review 1.  The 'sweet' and 'bitter' involvement of glycosaminoglycans in lung diseases: pharmacotherapeutic relevance.

Authors:  Eleni Papakonstantinou; George Karakiulakis
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

Review 2.  Bench-to-bedside review: the role of glycosaminoglycans in respiratory disease.

Authors:  Alba B Souza-Fernandes; Paolo Pelosi; Patricia R M Rocco
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

3.  Selective permeabilization of the blood-brain barrier at sites of metastasis.

Authors:  John J Connell; Grégoire Chatain; Bart Cornelissen; Katherine A Vallis; Alastair Hamilton; Len Seymour; Daniel C Anthony; Nicola R Sibson
Journal:  J Natl Cancer Inst       Date:  2013-10-09       Impact factor: 13.506

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.